7 results match your criteria: "Cantonal Clinic St. Gallen[Affiliation]"
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.
RMD Open
July 2024
Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland.
Objective: To evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the SELECT-BEYOND phase 3 trial.
Methods: Patients refractory to ≥1 biological disease-modifying antirheumatic drug (DMARD) received upadacitinib 15 mg or 30 mg once daily or placebo, in combination with background conventional synthetic DMARD(s). At week 12, patients randomised to placebo were switched to upadacitinib 15 mg or 30 mg.
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
Rheumatol Ther
October 2024
Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Introduction: The safety and efficacy of upadacitinib 15 mg (UPA15) through week 216 was evaluated in patients with rheumatoid arthritis (RA) from the long-term extension (LTE) of the phase 3 SELECT-CHOICE study.
Methods: Patients with RA refractory to biologic disease-modifying antirheumatic drugs (bDMARDs) were randomized to UPA15 or abatacept (ABA) for 24 weeks. During the open-label LTE, patients on ABA switched to UPA15 at week 24, and those on UPA15 continued treatment.
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Rheumatol Ther
June 2024
Department of Medicine/Rheumatology, University of California San Francisco, 400 Parnassus Ave B1, San Francisco, CA, 94143, USA.
Article Synopsis
- This study analyzed the safety of upadacitinib, an oral medication, over five years in patients with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA), based on data from multiple clinical trials.
- Results showed that 1789 patients received either upadacitinib or adalimumab, with higher rates of treatment-emergent adverse events (TEAEs) reported in the PsA group taking upadacitinib compared to those on adalimumab, especially regarding serious infections and certain cancers.
- The findings suggest that while
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
Rheumatol Ther
February 2024
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Article Synopsis
- This article investigates cancer occurrences in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) who were treated with upadacitinib (UPA) compared to other treatments.
- The study analyzed data from 11 phase 3 clinical trials, assessing adverse events related to treatment, specifically focusing on malignancies and distinguishing between nonmelanoma skin cancer and other cancers.
- The findings indicate comparable rates of cancer (excluding nonmelanoma skin cancer) across different treatments, with a notable increase in nonmelanoma skin cancer rates
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Rheumatol Ther
April 2022
Northwestern University Feinberg School of Medicine, 420 E Superior St., Chicago, IL, 60611, USA.
Article Synopsis
- This analysis evaluates the safety of upadacitinib, a medication for psoriatic arthritis, over three years for patients with inadequate prior treatment responses.
- The study pooled safety data from two phase 3 trials, comparing upadacitinib (15 mg and 30 mg) against placebo and adalimumab, focusing on treatment-emergent adverse events (TEAEs) and laboratory results.
- Results showed that common TEAEs with upadacitinib included upper respiratory infections and elevated creatine phosphokinase, with similar rates of serious events (malignancies, cardiovascular issues) between treatments, although herpes zoster and certain infections were more frequent with upadacitinib.
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. Reply.
N Engl J Med
January 2021
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
N Engl J Med
October 2020
From the Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland (A.R.-R.); AbbVie, North Chicago, IL (J.E., A.L.P., N.K., Y.Z., N.M.); Centre Hospitalier de l'Université de Montréal, Montreal (B.H.); Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (M.R.); and Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (R.M.X.).
Background: Upadacitinib is an oral selective Janus kinase inhibitor to treat rheumatoid arthritis. The efficacy and safety of upadacitinib as compared with abatacept, a T-cell costimulation modulator, in patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (DMARDs) are unclear.
Methods: In this 24-week, phase 3, double-blind, controlled trial, we randomly assigned patients in a 1:1 ratio to receive oral upadacitinib (15 mg once daily) or intravenous abatacept, each in combination with stable synthetic DMARDs.